. Author manuscript; available in PMC: 2020 Jun 1.

Published in final edited form as: Pharmacol Biochem Behav. 2019 May 10;181:86–92. doi: 10.1016/j.pbb.2019.05.004

Table 1.

Demographic information for randomized sample.

	Galantamine (n = 18)	Placebo (n = 16)	Total Sample (N = 34)
	N (%)
*Sex*
Male	15 (83.3)	10 (62.5)	25 (73.5)
Female	3 (16.7)	6 (37.5)	9 (26.5)
*Ethnicity*
White	3 (16.7)	3 (18.8)	6 (17.6)
Black	14 (77.8)	12 (75.0)	26 (76.5)
Hispanic	1 (5.6)	1 (6.3)	2 (5.9)
*Current Smoker*	11 (61.1)	11 (68.8)	22 (64.7)
	Mean (SD)
*Age*	30.2 (8.0)	29.8 (9.7)	30 (8.8)
*Cannabis use (joints per day^	2.2 (1.3)	1.7 (1.0)	2.0 (1.2)
*Years of cigarette smoking*	9.3 (9.8)	7.4 (9.0)	8.4 (9.3)
*Years of education completed*	12.4 (1.0)	12.6 (1.1)	12.5 (1.0)

There were no significant differences between conditions on any of the baseline assessment variables (p-values > 0.05).

Cannabis use data were missing for 2 participants in the placebo group.